PTPRF — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1301664	0.49	13/20
SCHEMBL1659911	0.60	11/20
SCHEMBL1659912	0.60	11/20
SCHEMBL1658006	0.53	11/20
SCHEMBL1657891	0.59	9/20
SCHEMBL1657894	0.59	9/20
SCHEMBL1657997	0.51	9/20
SCHEMBL1659758	0.50	9/20
SCHEMBL783749	0.47	5/20
SCHEMBL1300889	0.40	5/20
SCHEMBL1301794	0.38	5/20
SCHEMBL1302486	0.37	5/20
SCHEMBL611071	0.46	4/20
SCHEMBL2190528	0.43	4/20
SCHEMBL2190532	0.43	4/20
SCHEMBL2190540	0.43	4/20
SCHEMBL69699	0.43	4/20
SCHEMBL1252724	0.41	4/20
SCHEMBL2192533	0.41	4/20
SCHEMBL1658888	0.39	4/20

Clinical trials — most relevant to PTPRF by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance	PHASE4	UNKNOWN
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia	PHASE3	RECRUITING
Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF	PHASE3	COMPLETED
Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation	PHASE2	UNKNOWN
Imatinib in Dermatofibrosarcoma Protuberans (DFSP)	PHASE1/PHASE2	COMPLETED
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)	PHASE1/PHASE2	WITHDRAWN
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma	PHASE2	RECRUITING
Pembrolizumab (MK-3475) in MM Patients With Residual Disease	PHASE2	COMPLETED
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer	PHASE2	COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer	PHASE2	COMPLETED
New Individualized Therapy Trial for Metastatic Colorectal Cancer	PHASE1/PHASE2	COMPLETED
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors	PHASE1	WITHDRAWN
Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers	PHASE1	COMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease	nan	UNKNOWN
Monitoring of Breathing Effort Through Pressure Time Product Measurement Using Airway Occlusion Pressure	nan	UNKNOWN
Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing	nan	RECRUITING
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients.	nan	COMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia	nan	UNKNOWN
Pulsed Electro Magnetic Fields (PEMF) in Depression	nan	COMPLETED
Cardiovascular Effects of Empagliflozine	nan	UNKNOWN
NCF Gene & TNFSF4 in SLE Patients	nan	UNKNOWN
K-RAS Oncogene Mutation in Patients With Advanced Non-Small Cell Lung Cancer Associated With Exposure to Wood Smoke and Tobacco Smoking: Therapeutic Implications	nan	COMPLETED
Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s)	nan	NOT_YET_RECRUITING
IVF Outcome in Polycystic Ovary Syndrome Patients	nan	UNKNOWN
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PTPRF binder may also engage these)

Protein	Name	Similarity
A7MBJ4	—	1.000	A7MBJ4 →
Q64604	—	1.000	Q64604 →
PTPRS	Receptor-type tyrosine-protein phosphatase S	0.998	landscape →
A2A8L5	—	0.996	A2A8L5 →
A4IFW2	—	0.993	A4IFW2 →
Q64605	—	0.992	Q64605 →
P23468	—	0.991	P23468 →
B0V2N1	—	0.988	B0V2N1 →
Q64487	—	0.988	Q64487 →
Q8AV58	—	0.985	Q8AV58 →
O94856	—	0.983	O94856 →
Q2EY15	—	0.981	Q2EY15 →
Q3UH53	—	0.981	Q3UH53 →
O97394	—	0.978	O97394 →
Q7Z5N4	—	0.978	Q7Z5N4 →
P16621	—	0.977	P16621 →
Q6V4S5	—	0.977	Q6V4S5 →
Q9QZS7	—	0.977	Q9QZS7 →
Q05695	—	0.976	Q05695 →
F1NWE3	—	0.976	F1NWE3 →
Q2VWP9	—	0.976	Q2VWP9 →
Q92823	—	0.976	Q92823 →
Q2VWP7	—	0.975	Q2VWP7 →
Q8AV57	—	0.975	Q8AV57 →
P97686	—	0.974	P97686 →
Q810U4	—	0.974	Q810U4 →
Q90478	—	0.974	Q90478 →
O55005	—	0.973	O55005 →
L1CAM	Neural cell adhesion molecule L1	0.973	landscape →
P11627	—	0.973	P11627 →